McMaster University

North Brunswick, N.J. – October 30, 2026 -- All five antibody-deficient mice treated with Lactiga's LCTG-001 survived influenza infection, compared with two of five in the control group, according to a peer-reviewed preclinical study conducted by McMaster University scientists in collaboration with Lactiga US, Inc.

The research was published in Science Advances on October 14, 2026. LCTG-001 is a nasal antibody treatment made from secretory immunoglobulin A (sIgA) purified from donated human breast milk. Lactiga is developing it for patients with common variable immunodeficiency (CVID) who keep getting respiratory infections despite existing therapies.

Hamilton, Ontario – – September 10, 2026 -- AtomVie Global Radiopharma has officially opened a new manufacturing plant at 10 Aeropark Boulevard in Hamilton, Ontario, representing an investment exceeding $160 million and marking the largest contract development and manufacturing organization (CDMO) site in North America dedicated to radiopharmaceutical production.

Facility spans 6,700 square meters and multiplies output tenfold

The site covers more than 6,700 square meters and increases AtomVie's production capacity by more than tenfold, supporting variable low-to-high throughput manufacturing. Modular spaces are designed to allow a smooth transition from early-stage clinical development to full commercial-scale production of radiopharmaceuticals.

Hamilton, Ontario – September 10, 2026 -- AtomVie Global Radiopharma has opened a new 72,300-square-foot production facility at 10 Aeropark Boulevard in Hamilton, Ontario, backed by more than $160 million in investment and marking the largest single-site radiopharmaceutical CDMO facility in North America.

New facility multiplies AtomVie's manufacturing output tenfold

The purpose-built plant increases AtomVie's production capacity by a factor of ten, supporting both low- and high-throughput manufacturing. The site is designed to handle the full lifecycle of radiopharmaceutical production, from early-stage clinical development through commercial-scale manufacturing, with flexible space reserved for future client requirements.

Hamilton, Ontario – September 09, 2026 -- AtomVie Global Radiopharma has opened a new $160 million manufacturing facility in Hamilton, Ontario, that the company calls the largest single-site radiopharmaceutical CDMO plant in North America.

New 72,300-square-foot plant multiplies manufacturing capacity tenfold

The purpose-built facility at 10 Aeropark Boulevard spans 72,300 square feet and increases AtomVie's manufacturing capacity by more than ten times its previous output. The site is designed to handle low- to high-volume production runs and supports a continuous path from early-stage clinical development through commercial-scale manufacturing.